Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 15% IN WATER vs MANNITOL 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic; increases plasma osmolality, drawing water from extravascular to intravascular space, thereby reducing intracranial and intraocular pressure.
Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure before irreversible renal failure occurs
Reduction of elevated intracranial pressure,Promotion of diuresis in acute renal failure,Reduction of intraocular pressure,Adjunct in treatment of acute oliguric renal failure,Management of cerebral edema
IV infusion of 50-200 g over 30-60 minutes as a 15% solution; typical adult dose is 1.5-2 g/kg every 6-8 hours.
Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.
Terminal elimination half-life is approximately 0.25–1.5 hours in patients with normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Terminal elimination half-life is 0.25–1.5 hours; prolonged in renal impairment (up to 36 hours).
Minimal hepatic metabolism; excreted unchanged by the kidneys.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration.
Primarily renal excretion as unchanged drug; >97% eliminated by glomerular filtration within 24 hours. Minimal biliary/fecal elimination (<3%).
Renal: >90% as unchanged drug; minimal biliary or fecal excretion.
Negligible (<5%) protein binding; does not bind significantly to albumin or other plasma proteins.
Negligible (<0.1%); no specific binding proteins.
Volume of distribution is approximately 0.4–0.6 L/kg, confined primarily to extracellular fluid; little intracellular penetration.
0.2–0.5 L/kg; primarily confined to extracellular fluid; increases with dehydration.
Not applicable (NA) due to intravenous administration only; oral bioavailability is negligible (not absorbed).
IV: 100%; oral: <10% due to poor absorption.
Contraindicated in anuria or severe renal impairment (e GFR < 10 m L/min); use with caution in mild to moderate impairment, monitor serum osmolarity and renal function.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. No specific dose for GFR >50 m L/min.
No specific adjustment for Child-Pugh class; monitor for volume overload and electrolyte disturbances in severe hepatic impairment.
No specific dose adjustment for hepatic impairment. Caution in patients with cirrhosis due to risk of fluid overload.
IV infusion of 0.25-2 g/kg as a 15-20% solution over 30-60 minutes; dosing based on weight and clinical response.
Children: For reduction of intracranial pressure, 0.25-1 g/kg as a 15-25% solution IV over 30-60 minutes. For diuresis, 0.5-2 g/kg as a 5-25% solution IV every 6-12 hours. Maximum dose 2 g/kg/dose.
Start at lower end of dosing range; monitor for fluid overload, electrolyte imbalances, and renal function due to age-related decreased reserve.
Elderly: Use lower doses and titrate carefully due to increased risk of fluid overload, electrolyte disturbances, and renal impairment. Monitor renal function and serum osmolarity. Start with the lower end of adult dosing range.
None FDA-approved.
None
Renal toxicity with high doses or prolonged use,Congestive heart failure exacerbation due to volume expansion,Electrolyte disturbances (hyponatremia, hypokalemia),Rapid infusion may cause hypotension and seizures,Use with caution in patients with anuria or pre-existing renal disease
May cause volume expansion and pulmonary edema in patients with impaired renal function. Monitor renal function, serum electrolytes, and fluid balance. Avoid extravasation as it may cause tissue necrosis. Use with caution in patients with congestive heart failure or severe dehydration.
Anuria due to severe renal disease,Well-established anuria due to severe renal disease,Pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, known hypersensitivity to mannitol.
No specific food interactions are documented. However, patients should maintain adequate hydration unless contraindicated. Diets high in sodium may exacerbate hypernatremia risk. Monitor fluid and electrolyte intake as directed by the clinician.
No significant food interactions; maintain adequate hydration unless contraindicated.
Osmitrol (mannitol) 15% in water is FDA pregnancy category C. Animal studies have not been conducted; no well-controlled human studies exist. Mannitol is a high-osmolar agent that can cause maternal osmotic diuresis and fluid/electrolyte disturbances, potentially affecting fetal homeostasis. Risk in first trimester is unknown; in second and third trimesters, use only if clearly needed due to potential for maternal pulmonary edema or heart failure.
Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First trimester: theoretical risk from osmotic shifts. Second/third trimester: monitor for maternal hemodynamic changes (e.g., pulmonary edema) that may affect placental perfusion.
It is unknown if mannitol is excreted in breast milk. In lactating women, breast-feeding is not recommended during IV infusion of high-dose mannitol due to possible infant exposure to high osmolar load. M/P ratio not available.
Unknown if excreted in human milk. No available data on M/P ratio. Consider benefits of breastfeeding vs. potential risk of osmotic effects or maternal dehydration. Caution advised.
No specific dose adjustments for pregnancy are established. Use with caution due to potential for altered renal function and fluid balance. Start with lowest effective dose, such as 50-100 g over 24 hours. Monitor closely for maternal volume overload.
No specific dose adjustments recommended for pregnancy alone. Consider increased plasma volume in pregnancy; monitor for volume overload. Dose based on clinical response and renal function. Avoid rapid infusion.
OSMITROL 15% IN WATER is a hypertonic solution for intravenous administration. Monitor serum sodium and osmolality closely to avoid hypernatremia and hyperosmolality. Ensure patency of IV line as extravasation can cause tissue necrosis. Use with caution in patients with renal impairment, heart failure, or hypovolemia. Rapid infusion can cause hemolysis. May cause osmotic diuresis leading to electrolyte depletion; monitor potassium and magnesium.
Administer via large-bore IV; monitor serum osmolality and renal function; ensure urine output >30 m L/h; avoid extravasation; use with caution in patients with pulmonary congestion or CHF.
This medication is given intravenously to reduce brain swelling or lower eye pressure.,Report any pain, redness, or swelling at the injection site immediately.,You may experience increased thirst or urination; this is expected due to the medication's effects.,Inform your healthcare provider if you have a history of kidney problems, heart failure, or dehydration.,Regular blood tests will be performed to monitor your electrolyte levels and kidney function.
You may experience increased urination during treatment.,Report any chest pain, difficulty breathing, or swelling to your doctor immediately.,You may feel thirsty or have a dry mouth; this is expected.,Your blood sugar levels may be monitored if you have diabetes.,Avoid consuming large amounts of salt or salty foods.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 15% IN WATER vs MANNITOL 10% IN PLASTIC CONTAINER, answered by our medical review team.
OSMITROL 15% IN WATER is a Osmotic Diuretic that works by Osmotic diuretic; increases plasma osmolality, drawing water from extravascular to intravascular space, thereby reducing intracranial and intraocular pressure.. MANNITOL 10% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 15% IN WATER and MANNITOL 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 15% IN WATER is: IV infusion of 50-200 g over 30-60 minutes as a 15% solution; typical adult dose is 1.5-2 g/kg every 6-8 hours.. The standard adult dose of MANNITOL 10% IN PLASTIC CONTAINER is: Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 15% IN WATER and MANNITOL 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 15% IN WATER is classified as Category C. Osmitrol (mannitol) 15% in water is FDA pregnancy category C. Animal studies have not been conducted; no well-controlled human studies exist. Mannitol is a high-osmolar agent that . MANNITOL 10% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.